The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer

Kevin D. Courtney, Mary Ellen Taplin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose of Review: The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent Findings: Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Summary: Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for patients with metastatic CRPC.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalCurrent Opinion in Oncology
Volume24
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Steroid 17-alpha-Hydroxylase
docetaxel
Therapeutics
Androgen Receptors
Mixed Function Oxygenases
Placebos
Survival
Population

Keywords

  • abiraterone acetate
  • ARN-509
  • castrate-resistant prostate cancer
  • MDV3100
  • second-line hormonal therapy
  • TAK-700
  • TOK-001

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. / Courtney, Kevin D.; Taplin, Mary Ellen.

In: Current Opinion in Oncology, Vol. 24, No. 3, 05.2012, p. 272-277.

Research output: Contribution to journalArticle

@article{02bc83b0c52a4ce68a1ed896332d3798,
title = "The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer",
abstract = "Purpose of Review: The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent Findings: Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Summary: Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for patients with metastatic CRPC.",
keywords = "abiraterone acetate, ARN-509, castrate-resistant prostate cancer, MDV3100, second-line hormonal therapy, TAK-700, TOK-001",
author = "Courtney, {Kevin D.} and Taplin, {Mary Ellen}",
year = "2012",
month = "5",
doi = "10.1097/CCO.0b013e328351059d",
language = "English (US)",
volume = "24",
pages = "272--277",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer

AU - Courtney, Kevin D.

AU - Taplin, Mary Ellen

PY - 2012/5

Y1 - 2012/5

N2 - Purpose of Review: The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent Findings: Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Summary: Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for patients with metastatic CRPC.

AB - Purpose of Review: The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent Findings: Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Summary: Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for patients with metastatic CRPC.

KW - abiraterone acetate

KW - ARN-509

KW - castrate-resistant prostate cancer

KW - MDV3100

KW - second-line hormonal therapy

KW - TAK-700

KW - TOK-001

UR - http://www.scopus.com/inward/record.url?scp=84859815355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859815355&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328351059d

DO - 10.1097/CCO.0b013e328351059d

M3 - Article

VL - 24

SP - 272

EP - 277

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -